| 產(chǎn)品編號(hào) | bsm-52535R |
| 英文名稱(chēng) | HLA-DR Recombinant Rabbit mAb |
| 中文名稱(chēng) | HLA-DR重組兔單抗 |
| 別 名 | DR alpha chain precursor; DRB1; DRB4; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DR alpha chain; HLA DR1B; HLA DR3B; HLA DRA; HLA DRA1; HLA DRB3; HLA DRB4; HLA DRB5; HLADR4B; HLADRA1; HLADRB; Major histocompatibility complex class II DR alpha; Major histocompatibility complex class II DR beta 1; Major histocompatibility complex class II DR beta 3; Major histocompatibility complex class II DR beta 4; Major histocompatibility complex class II DR beta 5; MGC117330; MHC cell surface glycoprotein; MHC class II antigen DRA; MHC II; DRA_HUMAN. |
 |
Specific References (1) | bsm-52535R has been referenced in 1 publications.
[IF=12.91] Kai Ye. et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen presenting cells in situ. MOL THER. 2022 Jun;: IHC ; Mouse.
|
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Recombinant |
| 克 隆 號(hào) | 32G3 |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ICC/IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 29 kDa |
| 檢測(cè)分子量 | |
| 細(xì)胞定位 | 細(xì)胞漿 細(xì)胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human HLA-DR between 150-250 amino acids |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq] Function: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. Subunit: Heterodimer of an alpha and a beta subunit; also referred as MHC class II molecule. In the endoplasmic reticulum (ER) it forms an heterononamer; 3 MHC class II molecules bind to a CD74 homotrimer (also known as invariant chain or HLA class II histocompatibility antigen gamma chain). Subcellular Location: Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, trans-Golgi network membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein. Lysosome membrane; Single-pass type I membrane protein. Late endosome membrane; Single-pass type I membrane protein. Note=The MHC class II complex transits through a number of intracellular compartments in the endocytic pathway until it reaches the cell membrane for antigen presentation. Post-translational modifications: Ubiquitinated by MARCH1 or MARCH8 at Lys-244 leading to down-regulation of MHC class II. When associated with ubiquitination of the beta subunit of HLA-DR: HLA-DRB4 'Lys-254', the down-regulation of MHC class II may be highly effective. Similarity: Belongs to the MHC class II family. Contains 1 Ig-like C1-type (immunoglobulin-like) domain. SWISS: P01903 Gene ID: 3122 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with HLA-DR monoclonal antibody, unconjugated (bsm-52535R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
Paraformaldehyde-fixed, paraffin embedded Human Spleen; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by conjugat
Paraformaldehyde-fixed, paraffin embedded Human Liver; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by conjugat
Paraformaldehyde-fixed, paraffin embedded Human Endometrial Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followe
Paraformaldehyde-fixed, paraffin embedded Human Gastric Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by
Paraformaldehyde-fixed, paraffin embedded Human Esophagus Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed b
Paraformaldehyde-fixed, paraffin embedded Human Colon; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by conjugati
Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by co
Paraformaldehyde-fixed, paraffin embedded Human Lung Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with HLA-DR Monoclonal Antibody, Unconjugated(bsm-52535R) at 1:200 overnight at 4°C, followed by con
|
